Download PDF
CC BY-NC-ND 4.0 · Exp Clin Endocrinol Diabetes
DOI: 10.1055/a-2301-3970
Article

Protective role of MerTK in diabetic peripheral neuropathy via inhibition of the NF-κb signaling pathway

Xiaoyang Su
1   First Affiliated Hospital of Kunming Medical University, Kunming, China (Ringgold ID: RIN36657)
,
Wenting Chen
1   First Affiliated Hospital of Kunming Medical University, Kunming, China (Ringgold ID: RIN36657)
,
Yidan Fu
1   First Affiliated Hospital of Kunming Medical University, Kunming, China (Ringgold ID: RIN36657)
,
Bian Wu
2   First People’s Hospital of Yunnan Province, Kunming, China
,
Fugang Mao
2   First People’s Hospital of Yunnan Province, Kunming, China
,
Yan Zhao
1   First Affiliated Hospital of Kunming Medical University, Kunming, China (Ringgold ID: RIN36657)
,
Qiuping Yang
1   First Affiliated Hospital of Kunming Medical University, Kunming, China (Ringgold ID: RIN36657)
,
Danfeng Lan
3   First People’s Hospital of Yunnan Province, Yunnan, China
› Author AffiliationsSupported by: National Natural Science Foundation of China 81860105
Supported by: the Yunnan Key Laboratory of Innovative Application of Traditional Chinese Medicine 202105AG070032
Supported by: the Yunnan Health Training Project of High Level Talents YNWR-QNBJ-2020-236
Supported by: the Special Joint Program of Yunnan Province 202001AY070001-159
› Further Information
Also available at
  PDF Download

Diabetic peripheral neuropathy impacts patient quality of life. Increased Mer tyrosine kinase expression has been demonstrated in such patients, yet its mechanism remains unclear. This study established type 2 diabetes mellitus and diabetic peripheral neuropathy models in Sprague Dawley rats via low-dose streptozotocin and a high-fat diet. Mer tyrosine kinase-specific inhibitors were administered by gavage once daily for 2 weeks. Sciatic nerve conduction velocity and nerve structure were measured. The levels of Mer tyrosine kinase, nuclear factor kappa-light-chain-enhancer of activated B cells, tumor necrosis factor-alpha, interleukin-1 beta, and relevant biochemical indexes were detected. The study revealed Mer tyrosine kinase upregulation in type 2 diabetes mellitus and more so in diabetic peripheral neuropathy groups. Inhibiting Mer tyrosine kinase led to reduced nerve conduction velocity and further deterioration of sciatic nerve structure, as evidenced by structural morphology. Concurrently, serum levels of total cholesterol, glycated hemoglobin, and triglyceride significantly rose. Moreover, nuclear factor kappa-light-chain-enhancer of activated B cells levels increased in both serum and nerve tissue, alongside a significant rise in tumor necrosis factor-alpha and interleukin-1 beta expressions. Mer tyrosine kinase was found to bind to inhibitor of kappa B kinase beta in Schwann cells, establishing inhibitor of kappa B kinase beta as a precursor to nuclear factor kappa-light-chain-enhancer of activated B cells activation. Inhibition of Mer tyrosine kinase exacerbates neuropathy, indicating its protective role in diabetic peripheral neuropathy by suppressing the nuclear factor kappa-light-chain-enhancer of activated B cells pathway, highlighting a potential new target for its diagnosis and treatment.



Publication History

Received: 28 November 2023

Accepted after revision: 03 April 2024

Accepted Manuscript online:
08 April 2024

© . The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany